Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.65
-0.14 (-2.42%)
Mar 20, 2026, 4:00 PM EDT - Market closed
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
412.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | 518.48K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 216.11M |
| Maravai LifeSciences Holdings | 185.74M |
| REGENXBIO | 170.44M |
| Ginkgo Bioworks Holdings | 170.16M |
| Century Therapeutics | 109.16M |
| Invivyd | 53.43M |
| X4 Pharmaceuticals | 35.11M |
| Entrada Therapeutics | 25.42M |
LXEO News
- 19 days ago - Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 6 weeks ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewsWire
- 7 weeks ago - Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript - Seeking Alpha
- 2 months ago - Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire